Table 3.

Multivariable logistic regression analyses for presence of CAC progression and linear regression analyses for extent of CAC progression/year.

	Presence of CAC Progression†		Extent of CAC Progression
	OR (95% CI)	p-value	β (SE)	p-value
Model 1: Log(baseline coronary artery calcium+1), Age, Site, Race/ethnicity, Menopausal status, Income, Education, Systolic blood pressure
C-reactive protein (mg/L)	0.96 (0.72–1.27)	0.8	0.0001 (0.006)	1.0
Fibrinogen (mg/dL)	0.82 (0.15–4.56)	0.8	−0.017 (0.037)	0.6
Plasminogen-activator inhibitor-1 (ng/mL)	1.93 (1.32–2.83)	0.0007	0.018 (0.008)	0.02
Tissue plasminogen activator antigen (ng/mL)	1.90 (0.83–4.31)	0.1	0.005 (0.017)	0.8
Factor VIIc (%)	2.43 (0.56–10.57)	0.2	0.034 (0.031)	0.3
Model 2: Model 1 + Body mass index
C-reactive protein (mg/L)	0.89 (0.65–1.21)	0.5	−0.006 (0.007)	0.4
Fibrinogen (mg/dL)	0.81 (0.14–4.65)	0.8	−0.035 (0.038)	0.4
Plasminogen-activator inhibitor-1 (ng/mL)	1.93 (1.31–2.85)	0.0009	0.016 (0.008)	0.06
Tissue plasminogen activator antigen (ng/mL)	1.81 (0.76–4.30)	0.2	−0.005 (0.018)	0.8
Factor VIIc (%)	2.43 (0.56–10.55)	0.2	0.034 (0.031)	0.3
Model 3: Model 2 + Log(Homeostasis Model Assessment), Family history of cardiovascular disease, High density lipoprotein cholesterol, Low density lipoprotein cholesterol, Log(triglycerides), Cardiovascular medication use, Current smoker
C-reactive protein (mg/L)	0.86 (0.61–1.22)	0.4	−0.0004 (0.007)	0.6
Fibrinogen (mg/dL)	0.77 (0.11–5.20)	0.8	−0.040 (0.040)	0.3
Plasminogen-activator inhibitor-1 (ng/mL)	1.91 (1.24–2.93)	0.003	0.017 (0.009)	0.06
Tissue plasminogen activator antigen (ng/mL)	1.42 (0.53–3.84)	0.5	−0.007 (0.020)	0.7
Factor VIIc (%)	1.58 (0.32–7.82)	0.6	0.030 (0.034)	0.4

All inflammatory/hemostatic biomarkers were log transformed.

^†CAC Progression: any CAC for baseline CAC=0, ≥10 for 0<baseline

CAC<100; ≥10% for baseline CAC ≥100

CAC = coronary artery calcium; CI = confidence interval; OR = odds ratio; SE = standard error